Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Identifieur interne : 003995 ( Main/Exploration ); précédent : 003994; suivant : 003996Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Auteurs : Jonathan L. Halperin [États-Unis] ; Graeme J. Hankey ; Daniel M. Wojdyla ; Jonathan P. Piccini ; Yuliya Lokhnygina ; Manesh R. Patel ; Günter Breithardt ; Daniel E. Singer ; Richard C. Becker ; Werner Hacke ; John F. Paolini ; Christopher C. Nessel ; Kenneth W. Mahaffey ; Robert M. Califf ; Keith A A. FoxSource :
- Circulation [ 1524-4539 ] ; 2014.
Descripteurs français
- KwdFr :
- Accident vasculaire cérébral (), Accident vasculaire cérébral (diagnostic), Accident vasculaire cérébral (épidémiologie), Administration par voie orale, Adulte d'âge moyen, Anticoagulants (administration et posologie), Anticoagulants (effets indésirables), Embolie (), Embolie (diagnostic), Embolie (épidémiologie), Femelle, Fibrillation auriculaire (diagnostic), Fibrillation auriculaire (traitement médicamenteux), Fibrillation auriculaire (épidémiologie), Humains, Hémorragie (), Hémorragie (diagnostic), Inhibiteurs du facteur Xa, Morpholines (administration et posologie), Morpholines (effets indésirables), Mâle, Méthode en double aveugle, Rivaroxaban, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Thiophènes (administration et posologie), Thiophènes (effets indésirables), Vitamine K (antagonistes et inhibiteurs), Warfarine (administration et posologie), Warfarine (effets indésirables).
- MESH :
- administration et posologie : Anticoagulants, Morpholines, Thiophènes, Warfarine.
- antagonistes et inhibiteurs : Vitamine K.
- diagnostic : Accident vasculaire cérébral, Embolie, Fibrillation auriculaire, Hémorragie.
- effets indésirables : Anticoagulants, Morpholines, Thiophènes, Warfarine.
- traitement médicamenteux : Fibrillation auriculaire.
- épidémiologie : Accident vasculaire cérébral, Embolie, Fibrillation auriculaire.
- Accident vasculaire cérébral, Administration par voie orale, Adulte d'âge moyen, Embolie, Femelle, Humains, Hémorragie, Inhibiteurs du facteur Xa, Mâle, Méthode en double aveugle, Rivaroxaban, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus.
English descriptors
- KwdEn :
- Administration, Oral, Aged, Aged, 80 and over, Anticoagulants (administration & dosage), Anticoagulants (adverse effects), Atrial Fibrillation (diagnosis), Atrial Fibrillation (drug therapy), Atrial Fibrillation (epidemiology), Double-Blind Method, Embolism (diagnosis), Embolism (epidemiology), Embolism (prevention & control), Factor Xa Inhibitors, Female, Hemorrhage (chemically induced), Hemorrhage (diagnosis), Humans, Male, Middle Aged, Morpholines (administration & dosage), Morpholines (adverse effects), Rivaroxaban, Stroke (diagnosis), Stroke (epidemiology), Stroke (prevention & control), Thiophenes (administration & dosage), Thiophenes (adverse effects), Treatment Outcome, Vitamin K (antagonists & inhibitors), Warfarin (administration & dosage), Warfarin (adverse effects).
- MESH :
- chemical , administration & dosage : Anticoagulants, Morpholines, Thiophenes, Warfarin.
- chemical , adverse effects : Anticoagulants, Morpholines, Thiophenes, Warfarin.
- chemical , antagonists & inhibitors : Vitamin K.
- chemically induced : Hemorrhage.
- diagnosis : Atrial Fibrillation, Embolism, Hemorrhage, Stroke.
- drug therapy : Atrial Fibrillation.
- epidemiology : Atrial Fibrillation, Embolism, Stroke.
- prevention & control : Embolism, Stroke.
- Administration, Oral, Aged, Aged, 80 and over, Double-Blind Method, Factor Xa Inhibitors, Female, Humans, Male, Middle Aged, Rivaroxaban, Treatment Outcome.
Abstract
Nonvalvular atrial fibrillation is common in elderly patients, who face an elevated risk of stroke but difficulty sustaining warfarin treatment. The oral factor Xa inhibitor rivaroxaban was noninferior to warfarin in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). This prespecified secondary analysis compares outcomes in older and younger patients.
DOI: 10.1161/CIRCULATIONAHA.113.005008
PubMed: 24895454
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003665
- to stream PubMed, to step Curation: 003552
- to stream PubMed, to step Checkpoint: 003552
- to stream Ncbi, to step Merge: 001A95
- to stream Ncbi, to step Curation: 001A95
- to stream Ncbi, to step Checkpoint: 001A95
- to stream Main, to step Merge: 003A36
- to stream Main, to step Curation: 003995
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).</title><author><name sortKey="Halperin, Jonathan L" sort="Halperin, Jonathan L" uniqKey="Halperin J" first="Jonathan L" last="Halperin">Jonathan L. Halperin</name><affiliation wicri:level="1"><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.). jonathan.halperin@mssm.edu.</nlm:affiliation><country wicri:rule="url">États-Unis</country></affiliation></author><author><name sortKey="Hankey, Graeme J" sort="Hankey, Graeme J" uniqKey="Hankey G" first="Graeme J" last="Hankey">Graeme J. Hankey</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Wojdyla, Daniel M" sort="Wojdyla, Daniel M" uniqKey="Wojdyla D" first="Daniel M" last="Wojdyla">Daniel M. Wojdyla</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Piccini, Jonathan P" sort="Piccini, Jonathan P" uniqKey="Piccini J" first="Jonathan P" last="Piccini">Jonathan P. Piccini</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Lokhnygina, Yuliya" sort="Lokhnygina, Yuliya" uniqKey="Lokhnygina Y" first="Yuliya" last="Lokhnygina">Yuliya Lokhnygina</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Patel, Manesh R" sort="Patel, Manesh R" uniqKey="Patel M" first="Manesh R" last="Patel">Manesh R. Patel</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Breithardt, Gunter" sort="Breithardt, Gunter" uniqKey="Breithardt G" first="Günter" last="Breithardt">Günter Breithardt</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Singer, Daniel E" sort="Singer, Daniel E" uniqKey="Singer D" first="Daniel E" last="Singer">Daniel E. Singer</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Becker, Richard C" sort="Becker, Richard C" uniqKey="Becker R" first="Richard C" last="Becker">Richard C. Becker</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Hacke, Werner" sort="Hacke, Werner" uniqKey="Hacke W" first="Werner" last="Hacke">Werner Hacke</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Paolini, John F" sort="Paolini, John F" uniqKey="Paolini J" first="John F" last="Paolini">John F. Paolini</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Nessel, Christopher C" sort="Nessel, Christopher C" uniqKey="Nessel C" first="Christopher C" last="Nessel">Christopher C. Nessel</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Mahaffey, Kenneth W" sort="Mahaffey, Kenneth W" uniqKey="Mahaffey K" first="Kenneth W" last="Mahaffey">Kenneth W. Mahaffey</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Califf, Robert M" sort="Califf, Robert M" uniqKey="Califf R" first="Robert M" last="Califf">Robert M. Califf</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Fox, Keith A A" sort="Fox, Keith A A" uniqKey="Fox K" first="Keith A A" last="Fox">Keith A A. Fox</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24895454</idno><idno type="pmid">24895454</idno><idno type="doi">10.1161/CIRCULATIONAHA.113.005008</idno><idno type="wicri:Area/PubMed/Corpus">003665</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003665</idno><idno type="wicri:Area/PubMed/Curation">003552</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003552</idno><idno type="wicri:Area/PubMed/Checkpoint">003552</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003552</idno><idno type="wicri:Area/Ncbi/Merge">001A95</idno><idno type="wicri:Area/Ncbi/Curation">001A95</idno><idno type="wicri:Area/Ncbi/Checkpoint">001A95</idno><idno type="wicri:Area/Main/Merge">003A36</idno><idno type="wicri:Area/Main/Curation">003995</idno><idno type="wicri:Area/Main/Exploration">003995</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).</title><author><name sortKey="Halperin, Jonathan L" sort="Halperin, Jonathan L" uniqKey="Halperin J" first="Jonathan L" last="Halperin">Jonathan L. Halperin</name><affiliation wicri:level="1"><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.). jonathan.halperin@mssm.edu.</nlm:affiliation><country wicri:rule="url">États-Unis</country></affiliation></author><author><name sortKey="Hankey, Graeme J" sort="Hankey, Graeme J" uniqKey="Hankey G" first="Graeme J" last="Hankey">Graeme J. Hankey</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Wojdyla, Daniel M" sort="Wojdyla, Daniel M" uniqKey="Wojdyla D" first="Daniel M" last="Wojdyla">Daniel M. Wojdyla</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Piccini, Jonathan P" sort="Piccini, Jonathan P" uniqKey="Piccini J" first="Jonathan P" last="Piccini">Jonathan P. Piccini</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Lokhnygina, Yuliya" sort="Lokhnygina, Yuliya" uniqKey="Lokhnygina Y" first="Yuliya" last="Lokhnygina">Yuliya Lokhnygina</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Patel, Manesh R" sort="Patel, Manesh R" uniqKey="Patel M" first="Manesh R" last="Patel">Manesh R. Patel</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Breithardt, Gunter" sort="Breithardt, Gunter" uniqKey="Breithardt G" first="Günter" last="Breithardt">Günter Breithardt</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Singer, Daniel E" sort="Singer, Daniel E" uniqKey="Singer D" first="Daniel E" last="Singer">Daniel E. Singer</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Becker, Richard C" sort="Becker, Richard C" uniqKey="Becker R" first="Richard C" last="Becker">Richard C. Becker</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Hacke, Werner" sort="Hacke, Werner" uniqKey="Hacke W" first="Werner" last="Hacke">Werner Hacke</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Paolini, John F" sort="Paolini, John F" uniqKey="Paolini J" first="John F" last="Paolini">John F. Paolini</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Nessel, Christopher C" sort="Nessel, Christopher C" uniqKey="Nessel C" first="Christopher C" last="Nessel">Christopher C. Nessel</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Mahaffey, Kenneth W" sort="Mahaffey, Kenneth W" uniqKey="Mahaffey K" first="Kenneth W" last="Mahaffey">Kenneth W. Mahaffey</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Califf, Robert M" sort="Califf, Robert M" uniqKey="Califf R" first="Robert M" last="Califf">Robert M. Califf</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author><author><name sortKey="Fox, Keith A A" sort="Fox, Keith A A" uniqKey="Fox K" first="Keith A A" last="Fox">Keith A A. Fox</name><affiliation><nlm:affiliation>From Icahn School of Medicine at Mount Sinai, New York, NY (J.L.H.); School of Medicine and Pharmacology, University of Western Australia School of Medicine and Pharmacology, Perth, Australia (G.J.H.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (D.M.W., J.P.P., Y.L., M.R.P.); University of Münster, Münster, Germany (G.B.); Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.E.S.); University of Cincinnati College of Medicine, Cincinnati, OH (R.C.B.); Ruprecht-Karls University, Heidelberg, Germany (W.H.); Cerenis Therapeutics, Labege, France (J.F.P.); Janssen Research and Development, Raritan, NJ (C.C.N.); Stanford University School of Medicine, Stanford, CA (K.W.M.); Duke Translational Medicine Institute, Duke University Medical Center, Durham, NC (R.M.C.); and University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).</nlm:affiliation><wicri:noCountry code="subField">United Kingdom (K.A.A.F.).</wicri:noCountry></affiliation></author></analytic><series><title level="j">Circulation</title><idno type="eISSN">1524-4539</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term><term>Aged</term><term>Aged, 80 and over</term><term>Anticoagulants (administration & dosage)</term><term>Anticoagulants (adverse effects)</term><term>Atrial Fibrillation (diagnosis)</term><term>Atrial Fibrillation (drug therapy)</term><term>Atrial Fibrillation (epidemiology)</term><term>Double-Blind Method</term><term>Embolism (diagnosis)</term><term>Embolism (epidemiology)</term><term>Embolism (prevention & control)</term><term>Factor Xa Inhibitors</term><term>Female</term><term>Hemorrhage (chemically induced)</term><term>Hemorrhage (diagnosis)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Morpholines (administration & dosage)</term><term>Morpholines (adverse effects)</term><term>Rivaroxaban</term><term>Stroke (diagnosis)</term><term>Stroke (epidemiology)</term><term>Stroke (prevention & control)</term><term>Thiophenes (administration & dosage)</term><term>Thiophenes (adverse effects)</term><term>Treatment Outcome</term><term>Vitamin K (antagonists & inhibitors)</term><term>Warfarin (administration & dosage)</term><term>Warfarin (adverse effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Accident vasculaire cérébral ()</term><term>Accident vasculaire cérébral (diagnostic)</term><term>Accident vasculaire cérébral (épidémiologie)</term><term>Administration par voie orale</term><term>Adulte d'âge moyen</term><term>Anticoagulants (administration et posologie)</term><term>Anticoagulants (effets indésirables)</term><term>Embolie ()</term><term>Embolie (diagnostic)</term><term>Embolie (épidémiologie)</term><term>Femelle</term><term>Fibrillation auriculaire (diagnostic)</term><term>Fibrillation auriculaire (traitement médicamenteux)</term><term>Fibrillation auriculaire (épidémiologie)</term><term>Humains</term><term>Hémorragie ()</term><term>Hémorragie (diagnostic)</term><term>Inhibiteurs du facteur Xa</term><term>Morpholines (administration et posologie)</term><term>Morpholines (effets indésirables)</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Rivaroxaban</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Thiophènes (administration et posologie)</term><term>Thiophènes (effets indésirables)</term><term>Vitamine K (antagonistes et inhibiteurs)</term><term>Warfarine (administration et posologie)</term><term>Warfarine (effets indésirables)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anticoagulants</term><term>Morpholines</term><term>Thiophenes</term><term>Warfarin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anticoagulants</term><term>Morpholines</term><term>Thiophenes</term><term>Warfarin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Vitamin K</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticoagulants</term><term>Morpholines</term><term>Thiophènes</term><term>Warfarine</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Vitamine K</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hemorrhage</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Atrial Fibrillation</term><term>Embolism</term><term>Hemorrhage</term><term>Stroke</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Accident vasculaire cérébral</term><term>Embolie</term><term>Fibrillation auriculaire</term><term>Hémorragie</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Atrial Fibrillation</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticoagulants</term><term>Morpholines</term><term>Thiophènes</term><term>Warfarine</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Atrial Fibrillation</term><term>Embolism</term><term>Stroke</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Embolism</term><term>Stroke</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Fibrillation auriculaire</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Accident vasculaire cérébral</term><term>Embolie</term><term>Fibrillation auriculaire</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Aged</term><term>Aged, 80 and over</term><term>Double-Blind Method</term><term>Factor Xa Inhibitors</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Rivaroxaban</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Accident vasculaire cérébral</term><term>Administration par voie orale</term><term>Adulte d'âge moyen</term><term>Embolie</term><term>Femelle</term><term>Humains</term><term>Hémorragie</term><term>Inhibiteurs du facteur Xa</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Rivaroxaban</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Nonvalvular atrial fibrillation is common in elderly patients, who face an elevated risk of stroke but difficulty sustaining warfarin treatment. The oral factor Xa inhibitor rivaroxaban was noninferior to warfarin in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). This prespecified secondary analysis compares outcomes in older and younger patients.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Becker, Richard C" sort="Becker, Richard C" uniqKey="Becker R" first="Richard C" last="Becker">Richard C. Becker</name><name sortKey="Breithardt, Gunter" sort="Breithardt, Gunter" uniqKey="Breithardt G" first="Günter" last="Breithardt">Günter Breithardt</name><name sortKey="Califf, Robert M" sort="Califf, Robert M" uniqKey="Califf R" first="Robert M" last="Califf">Robert M. Califf</name><name sortKey="Fox, Keith A A" sort="Fox, Keith A A" uniqKey="Fox K" first="Keith A A" last="Fox">Keith A A. Fox</name><name sortKey="Hacke, Werner" sort="Hacke, Werner" uniqKey="Hacke W" first="Werner" last="Hacke">Werner Hacke</name><name sortKey="Hankey, Graeme J" sort="Hankey, Graeme J" uniqKey="Hankey G" first="Graeme J" last="Hankey">Graeme J. Hankey</name><name sortKey="Lokhnygina, Yuliya" sort="Lokhnygina, Yuliya" uniqKey="Lokhnygina Y" first="Yuliya" last="Lokhnygina">Yuliya Lokhnygina</name><name sortKey="Mahaffey, Kenneth W" sort="Mahaffey, Kenneth W" uniqKey="Mahaffey K" first="Kenneth W" last="Mahaffey">Kenneth W. Mahaffey</name><name sortKey="Nessel, Christopher C" sort="Nessel, Christopher C" uniqKey="Nessel C" first="Christopher C" last="Nessel">Christopher C. Nessel</name><name sortKey="Paolini, John F" sort="Paolini, John F" uniqKey="Paolini J" first="John F" last="Paolini">John F. Paolini</name><name sortKey="Patel, Manesh R" sort="Patel, Manesh R" uniqKey="Patel M" first="Manesh R" last="Patel">Manesh R. Patel</name><name sortKey="Piccini, Jonathan P" sort="Piccini, Jonathan P" uniqKey="Piccini J" first="Jonathan P" last="Piccini">Jonathan P. Piccini</name><name sortKey="Singer, Daniel E" sort="Singer, Daniel E" uniqKey="Singer D" first="Daniel E" last="Singer">Daniel E. Singer</name><name sortKey="Wojdyla, Daniel M" sort="Wojdyla, Daniel M" uniqKey="Wojdyla D" first="Daniel M" last="Wojdyla">Daniel M. Wojdyla</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Halperin, Jonathan L" sort="Halperin, Jonathan L" uniqKey="Halperin J" first="Jonathan L" last="Halperin">Jonathan L. Halperin</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003995 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003995 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24895454
|texte= Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24895454" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |